增强CT对比平扫低剂量CT在18F-FDG高摄取淋巴瘤PET/CT分期与疗效评估中的诊断贡献:一项前瞻性研究
该前瞻性研究纳入170例18F-FDG高摄取淋巴瘤患者的PET/CT扫描(分期85例,疗效评估85例),比较增强CT(CECT)与平扫CT(UECT)以PET/CT为金标准的诊断价值。CECT仅在3例分期组(3.5%)中识别出额外结外病灶并改变分期,疗效评估中CECT与UECT完全一致;CECT的附加诊断价值低于临床相关性阈值(15%),McNemar检验两组均无统计学显著性。结论认为可能无需在分期和疗效评估中常规进行CECT检查。
要点
- CECT仅在3.5%的分期病例中识别额外结外病灶并改变分期。
- 疗效评估中CECT与UECT结果完全一致。
- CECT附加诊断价值低于预设的15%临床相关性阈值。
核心结论
- 在18F-FDG高摄取淋巴瘤的分期和疗效评估中,CECT相较于UECT的附加诊断价值有限,可能可以省略CECT检查。
研究设计与样本
- 前瞻性研究,纳入170例18F-FDG高摄取淋巴瘤患者的PET/UECT及后续CECT扫描,分期组85例、疗效评估组85例,使用一体化64排PET/CT扫描仪单次 session 完成。
- CECT和UECT图像由2名放射科医生分别评估,PET图像由2名核医学医生评估,以PET/CT结果为金标准。
主要发现
- CECT仅在3例分期组病例(3.5%)中识别出额外结外病灶(肝脏、肌肉和胃),导致与UECT相比分期不同。
- 疗效评估中CECT与UECT之间完全一致。
- CECT的附加诊断价值低于预设的临床相关性阈值(15%)。
- McNemar检验在两组中均未显示统计学显著性。
- CECT检出而UECT未检出的偶然发现对临床管理重要,但不足以改变淋巴瘤治疗策略。
关键数值与推荐
- 结内和结外UECT及CECT发现根据Lugano标准分类,并与作为金标准的PET/CT结果进行比较。
- 使用McNemar检验对配对数据分别计算UECT和CECT与PET确定的疾病状态的一致率。
临床怎么用
- 对于18F-FDG高摄取淋巴瘤的分期和疗效评估,可考虑省略CECT检查,以减少辐射暴露和对比剂相关风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The aim of this study was to assess the added diagnostic value of contrast-enhanced CT (CECT) as compared with unenhanced CT (UECT) in PET/CT staging and treatment response assessment of 18F-FDG-avid lymphomas. Methods: 170 PET/UECT scans followed by CECT scans were prospectively performed for staging (n = 85) and for treatment response assessment (n = 85) of 18F-FDG-avid lymphomas, during a single session using an integrated 64-slice PET/CT scanner. CECT and UECT images were evaluated separately by 2 radiologists, whereas PET images were evaluated by 2 nuclear physicians. Nodal and extranodal UECT and CECT findings were classified according to the Lugano criteria and were successively compared with PET/CT results, considered the gold standard. In the analyzed groups, the agreement rate with the disease status determined via PET was calculated separately for UECT and CECT using the McNemar test on paired data. The added value of the contrast medium was shown by the agreement between the PET and CECT results and the lack of agreement between UECT and PET. Results: CECT enabled the identification of additional extranodal lesions (hepatic, muscular, and gastric) in only 3 staging group cases (3.5%), indicating different stages as compared with UECT, whereas there was absolute agreement between CECT and UECT in terms of treatment response assessment. The added diagnostic value of CECT was lower than the established threshold for clinical relevance (15%). The McNemar test indicated no statistical significance in either group. The incidental findings detected by CECT but not UECT were important for clinical management but not sufficient to alter lymphoma treatment strategy. Conclusion: According to our results, it might be possible to exclude CECT examination of 18F-FDG-avid lymphoma from staging and treatment response assessment, with the consequent advantages of reducing radiation exposure and potential contrast-related risks.
引用
- Marchetti L, Perrucci L, Pellegrino F, et al. Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of 18F-FDG-Avid Lymphomas: A Prospective Study. J Nucl Med. 2021. PMID: 33712534. doi:10.2967/jnumed.120.259242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。